FIGURE 4.

Differentially expressed genes included in significant pathways associated with current versus never regular‐dose aspirin use in type II ovarian tumors. (A) Differentially expressed inflammatory pathway genes that are associated with current versus never regular‐dose aspirin use in type II ovarian tumors. Within the significant pathways (i.e., TNFa signaling via NFkB, interferon alpha response, and interferon‐gamma response), individual genes that are associated with current regular‐dose aspirin use with unadjusted p‐value<0.10 were included in the heatmap. (B) Differentially expressed extracellular matrix architecture pathway genes that are associated with current regular‐dose aspirin use versus never aspirin use in type II ovarian tumors. Within the significant pathways (i.e., extracellular matrix organization, integrin cell surface interactions, degradation of the extracellular matrix, collagen biosynthesis and modifying enzymes, collagen degradation, collagen formation, collagen chain trimerization, assembly of collagen fibrils and other multimeric structures, ECM proteoglycans, and ECM receptor interaction), individual genes that were associated with current regular‐dose aspirin use with unadjusted p‐value<0.10 were included in the heatmap.